7 results about "Pranoprofen" patented technology

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

The utility model discloses a pranoprofen eye drop quantitative filling device, which relates to the technical field of eye drop filling, and comprises a filling pipe and a quantitative component, the lower end of the filling pipe is connected with a quantitative pipe, the front side of the quantitative pipe is provided with an observation window, the quantitative component for quantitative filling is arranged in the quantitative pipe, and the observation window is arranged on the front side of the quantitative pipe. And the quantitative assembly comprises an inner mounting frame, a protection pipe, a hydraulic rod, a top partition plate, a connecting rod and a bottom partition plate, the protection pipe is installed in the middle of the lower end of the inner mounting frame, the hydraulic rod is arranged in the protection pipe, and the output end of the hydraulic rod is connected with the top partition plate. According to the quantitative filling device for the pranoprofen eye drops, the inner sides of the top partition plate and the bottom partition plate play a quantitative liquid separation role on the eye drops, when the bottom partition plate further moves downwards to exceed the bottom of the quantitative tube, the quantitative eye drops are filled through the filling head, and at the moment, the top partition plate plays a separation role on the eye drops in the liquid storage box in the quantitative tube; the eye drops are prevented from being polluted.

To provide a novel ophthalmic composition. [Solution] The ophthalmic composition is composed of (A) one or more selected from the group consisting of pranoprofen and its salts, and (B) one or more selected from the group consisting of epinastine and its salts.

The invention discloses pranoprofen eye drops and a preparation method thereof. The eye drops comprise pranoprofen, a chitosan derivative, a nonionic thickener, borax, boric acid, a metal ion chelating agent and an osmotic pressure regulator. By adding the chitosan derivative and the nonionic thickening agent, pranoprofen can be continuously and slowly released, so that a longer effective concentration is maintained at an acting part, the administration frequency is reduced, and the medication compliance of a patient is improved.

The present disclosure relates to the technical field of pharmaceutical preparations, and provides a pharmaceutical preparation containing pranoprofen and a preparation method thereof. 5H-[1]-benzopyrano[2,3-b]pyridine-5-one is subjected to a reduction reaction and a dehydroxylation conversion to obtain 5H-[1]-benzopyrano[2,3-b]pyridine; the 5H-[1]-benzopyrano[2,3-b]pyridine is subjected to an acylation reaction to obtain a 2-halogenated propionyl substituted benzopyranopyridine intermediate; the 2-halogenated propionyl substituted benzopyranopyridine intermediate is treated to obtain crude pranoprofen; the crude pranoprofen is subjected to recrystallization to obtain pranoprofen wet crystals, and the pranoprofen wet crystals are added into an aqueous dispersion solvent to obtain the pharmaceutical preparation containing pranoprofen. The adverse effects of impurity accumulation in the synthesis process in the early stage are reduced, and the dispersion stability of the preparation in the later stage is improved, so that the dispersion stability of the preparation from the early stage to the later stage is realized.

The invention discloses pranoprofen eye drops and a production process thereof. Comprising the following raw material components in parts by weight: 0.1 to 0.5 part of pranoprofen, 1 to 5 parts of vitamin E polyethylene glycol 1000 succinate, 2 to 6 parts of soybean phospholipid, 3 to 8 parts of polyoxyethylated castor oil EL-40, 0.1 to 0.3 part of histidine, 0.2 to 0.6 part of sodium dihydrogen phosphate, 0.3 to 0.7 part of disodium hydrogen phosphate, 2 to 5 parts of glycerol, 1 to 4 parts of polyethylene glycol 400, 0.05 to 0.2 part of sodium hyaluronate, 0.1 to 0.4 part of D-panthenol and 0.01 to 0.03 part of benzalkonium chloride. The injection comprises the following components in parts by weight: 0.05-0.15 part of potassium sorbate, 0.005-0.02 part of epsilon-polylysine, 0.01-0.05 part of edetate disodium, 0.02-0.08 part of vitamin E acetate, 0.005-0.015 part of L-cysteine and the balance of water for injection, and the total weight part of the water for injection is 100 parts. According to the invention, pranoprofen is taken as a core, and vitamin E polyethylene glycol 1000 succinate, soybean phospholipid and polyoxyethylated castor oil EL-40 are adopted for synergistic solubilization, so that the problem of poor water solubility of the medicine is solved; histidine and phosphate are compounded for buffering and are matched with multiple stabilizers, so that the stability of the preparation is improved.

The invention provides a candidate medicine for promoting the embryo implantation efficiency of an endometritis type RIF patient, and belongs to the technical field of embryo implantation. In order to solve the problem of how to discover potential intervention drugs aiming at the endometritis type RIF pathological mechanism, a five-step efficient drug screening strategy based on an in-vitro implantation model of the endometritis type RIF is adopted, so that the reliability and function correlation of a screening result are ensured. According to the invention, a candidate drug screened by adopting a five-step method efficient drug screening strategy comprises any one of the following drugs: evocamide, choline, nitrendipine, megestrol acetate, pranoprofen, oxaliplatin, adenine, ensorizole, baicalin and diacerein. Evocamide, choline and nitrendipine in the candidate drugs are three drugs with the best implantation promotion efficiency for patients with endometritis type RIF.